Rethinking Pain: A Dual-Target Approach Leveraging GABA-A & DHODH Modulation
8:00 am - Wednesday 28th January 2026
- Gain insights from Phase 2a clinical data of AP-325 in neuropathic pain and its impact on patient outcomes
- Understand the next steps in clinical development and how this therapy could shape future treatment strategies
- Explore the potential of dual-target mechanisms to deliver more effective, long-term pain relief
New Data
